EUDA EUDA HEALTH HLDGS LTD

EUDA Subsidiary CK Health Plus Secures Malaysia Direct Selling License, Strengthening Its Longevity Business Across Asia

EUDA Subsidiary CK Health Plus Secures Malaysia Direct Selling License, Strengthening Its Longevity Business Across Asia

SINGAPORE, Oct. 20, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, CK Health Plus Sdn. Bhd. (“CK Health Plus”), has been granted a Direct Selling License (AJL 932509) (the “License”) by the Malaysian Ministry of Domestic Trade and Cost of Living.

License Approval and Compliance

The License marks a major milestone for CK Health Plus, allowing it to compliantly conduct direct selling and multi-level marketing operations nationwide. CK Health Plus is now authorized to recruit members, distribute wellness products, and operate its network marketing model in full compliance with Malaysia’s Direct Selling Act 1993.

Expansion and Strategic Rollout

With the License in place, the Company is poised to accelerate its nationwide rollout of Bioenergy Capsule Centers, expand EUDA Helixé supplement distribution, and strengthen synergies across its agent network in Malaysia and Singapore. CK Health Plus aims to redefine non-invasive and preventive healthcare through accessible, technology-driven solutions and entrepreneurial opportunities for its growing community.

Building an Ethical Preventative Healthcare Network

CK Health Plus is redefining how health, business, and education intersect. Every agent undergoes product knowledge training to ensure accuracy in wellness education and ethical engagement with customers. Through this comprehensive system, CK Health Plus aims to create a sustainable model where financial success and social impact align. The Company’s goal is to position Malaysia as a hub for accessible, science-based longevity solutions that combine technology, wellness, and entrepreneurship.

Executive Commentary

Mr. Alex Lai, CEO of CK Health Plus, commented:

“Recieving this License gives us the operational framework and momentum to drive our expansion at scale. It allows us to empower more people to take control of their health while also creating opportunities for those who want to build meaningful businesses in the non-invasive wellness industry. We are building an ecosystem that merges science, wellness, and entrepreneurship. Every agent represents a node in the network that will carry forward our mission of preventive healthcare.”

About EUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

Forward-Looking Statements

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s and CK Health Plus control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Christensen Advisory

Linda Bergkamp

Phone:

E-mail:



EN
20/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on EUDA HEALTH HLDGS LTD

 PRESS RELEASE

EUDA Subsidiary CK Health Plus Secures Malaysia Direct Selling License...

EUDA Subsidiary CK Health Plus Secures Malaysia Direct Selling License, Strengthening Its Longevity Business Across Asia SINGAPORE, Oct. 20, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, CK Health Plus Sdn. Bhd. (“CK Health Plus”), has been granted a Direct Selling License (AJL 932509) (the “License”) by the Malaysian Ministry of Domestic Trade and Cost of Living. License Approval and Com...

 PRESS RELEASE

EUDA Signs Letter of Intent to Potentially Acquire GO POSB

EUDA Signs Letter of Intent to Potentially Acquire GO POSB SINGAPORE, Sept. 10, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has signed a Letter of Intent (the “LOI”) to potentially acquire GO POSB Organoids Pte Ltd (“GO POSB”), a biotechnology company formed in Singapore. GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) pla...

 PRESS RELEASE

EUDA Strategically Expands into T-Cell Immunotherapy – Strengthening I...

EUDA Strategically Expands into T-Cell Immunotherapy – Strengthening Its Stem Cell Therapy Portfolio SINGAPORE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a leading Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China, today announced that it has secured distribution rights for T-cell immunotherapies in Malaysia developed by Shenzhen Inno Immune Co. Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutic and customized medicines for a wide range of diseases in ...

 PRESS RELEASE

EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd

EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent (the “LOI”) to potentially acquire Chemokine Pte Ltd (“Chemokine”). EUDA will carry out due diligence on Chemokine, subject to confidentiality obligations. Chemokine has agreed to an exclusivity period of at least one hundred and twenty (120) d...

 PRESS RELEASE

EUDA Expands Wellness Product Portfolio With A Next-Generation Immune ...

EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement SINGAPORE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd., has secured exclusive worldwide distribution rights for a next-generation immune health supplement (the “Supplement”) from Chemokine Pte. Ltd. (“Chemokine”), a Singapore-based biotech company focused on mole...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch